Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families

The distribution of BRCA1/2 germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean population, there are only two reports of mutation analysis of BRCA1/2 , and these included a low number of BC and/or OC patients. Moreover, the prevalence of B...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast cancer research and treatment 2011-04, Vol.126 (3), p.705-716
Hauptverfasser: Gonzalez-Hormazabal, Patricio, Gutierrez-Enriquez, Sara, Gaete, Daniel, Reyes, Jose M., Peralta, Octavio, Waugh, Enrique, Gomez, Fernando, Margarit, Sonia, Bravo, Teresa, Blanco, Rafael, Diez, Orland, Jara, Lilian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 716
container_issue 3
container_start_page 705
container_title Breast cancer research and treatment
container_volume 126
creator Gonzalez-Hormazabal, Patricio
Gutierrez-Enriquez, Sara
Gaete, Daniel
Reyes, Jose M.
Peralta, Octavio
Waugh, Enrique
Gomez, Fernando
Margarit, Sonia
Bravo, Teresa
Blanco, Rafael
Diez, Orland
Jara, Lilian
description The distribution of BRCA1/2 germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean population, there are only two reports of mutation analysis of BRCA1/2 , and these included a low number of BC and/or OC patients. Moreover, the prevalence of BRCA1/2 genomic rearrangements in Chilean and in other South American populations is unknown. In this article, we present the mutation-detection data corresponding to a set of 326 high-risk families analyzed by conformation-sensitive gel electrophoresis and heteroduplex analysis. To determine the contribution of BRCA1/2 LGRs in Chilean BC patients, we analyzed 56 high-risk subjects with no pathogenic BRCA1/2 point mutations. Germline BRCA1 / 2 point mutations were found in 23 (7.1%) of the 326 Chilean families. Families which had at least three BC and/or OC cases showed the highest frequency of mutations (15.9%). We identified 14 point pathogenic mutations. Three recurrent mutations in BRCA1 (c.187_188delAG, c.2605_2606delTT, and c.3450_3453delCAAG) and three in BRCA2 (c.4969_4970insTG, c.5374_5377delTATG, and c.6503_6504delTT) contributed to 63.6 and 66.7% of all the deleterious mutations of each gene, which may reflect the presence of region-specific founder effects. Taken together BRCA1/2 recurrent point mutations account for 65.2% (15/23) of the BRCA1/2 (+) families. No large deletions or duplications involving BRCA1 / 2 were identified in a subgroup of 56 index cases negative for BRCA1/2 point mutations. Our study, which is the largest conducted to date in a South American population, provides a comprehensive analysis on the type and distribution of BRCA1/2 mutations and allelic variants.
doi_str_mv 10.1007/s10549-010-1170-y
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_857482891</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A355939429</galeid><sourcerecordid>A355939429</sourcerecordid><originalsourceid>FETCH-LOGICAL-c574t-c76eb9c2a2c2431537eea4300793376ee533f65acf0ec2a7f9bd3de763bd5cfe3</originalsourceid><addsrcrecordid>eNp9ktuO0zAQhiMEYruFB-AGWaAFbrL1IY7jy1JxklZC4nAduc649ZLYxU6Q-vZMaWFZBMgX1mi-mdE_8xfFI0YvGaVqkRmVlS4poyVjipb7O8WMSSVKxZm6W8woq1VZN7Q-K85zvqaUakX1_eKM00bqWqlZkT7uwI5pGkh05OWH1ZItONlFH0YyTKMZfQyZmNCRDYQ4eEsSmJRM2MAAYczEB7L1m22ZfP5C1pjM4yJ-M8mbQKwJFhJZbX0PGDoz-N5DflDcc6bP8PD0z4vPr199Wr0tr96_ebdaXpVWqmosraphrS033PJKMCkUgKkE6tZCYA6kEK6WxjoKSCmn153oQNVi3UnrQMyL58e-uxS_TpDHdvDZQt-bAHHKbYNjGt5ohuSL_5KMMqWbmlca0Sd_oNdxSgF1YL-mUkxSidDTI7QxPbQ-uDgmYw8926WQUgtd8UOry79Q-DrARccADvd2u-DZbwVbMP24zbGffhzpNsiOoE0x5wSu3SU_mLRHJe3BOe3ROS09xOicdo81j0_CpvUA3a-Kn1ZB4OIEmGxN79AE1ucbTuiGUzzNvOBHLmMKfZJuNvTv6d8BAkTZcQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>858471505</pqid></control><display><type>article</type><title>Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Gonzalez-Hormazabal, Patricio ; Gutierrez-Enriquez, Sara ; Gaete, Daniel ; Reyes, Jose M. ; Peralta, Octavio ; Waugh, Enrique ; Gomez, Fernando ; Margarit, Sonia ; Bravo, Teresa ; Blanco, Rafael ; Diez, Orland ; Jara, Lilian</creator><creatorcontrib>Gonzalez-Hormazabal, Patricio ; Gutierrez-Enriquez, Sara ; Gaete, Daniel ; Reyes, Jose M. ; Peralta, Octavio ; Waugh, Enrique ; Gomez, Fernando ; Margarit, Sonia ; Bravo, Teresa ; Blanco, Rafael ; Diez, Orland ; Jara, Lilian</creatorcontrib><description>The distribution of BRCA1/2 germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean population, there are only two reports of mutation analysis of BRCA1/2 , and these included a low number of BC and/or OC patients. Moreover, the prevalence of BRCA1/2 genomic rearrangements in Chilean and in other South American populations is unknown. In this article, we present the mutation-detection data corresponding to a set of 326 high-risk families analyzed by conformation-sensitive gel electrophoresis and heteroduplex analysis. To determine the contribution of BRCA1/2 LGRs in Chilean BC patients, we analyzed 56 high-risk subjects with no pathogenic BRCA1/2 point mutations. Germline BRCA1 / 2 point mutations were found in 23 (7.1%) of the 326 Chilean families. Families which had at least three BC and/or OC cases showed the highest frequency of mutations (15.9%). We identified 14 point pathogenic mutations. Three recurrent mutations in BRCA1 (c.187_188delAG, c.2605_2606delTT, and c.3450_3453delCAAG) and three in BRCA2 (c.4969_4970insTG, c.5374_5377delTATG, and c.6503_6504delTT) contributed to 63.6 and 66.7% of all the deleterious mutations of each gene, which may reflect the presence of region-specific founder effects. Taken together BRCA1/2 recurrent point mutations account for 65.2% (15/23) of the BRCA1/2 (+) families. No large deletions or duplications involving BRCA1 / 2 were identified in a subgroup of 56 index cases negative for BRCA1/2 point mutations. Our study, which is the largest conducted to date in a South American population, provides a comprehensive analysis on the type and distribution of BRCA1/2 mutations and allelic variants.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-010-1170-y</identifier><identifier>PMID: 20859677</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adult ; Biological and medical sciences ; BRCA1 protein ; BRCA2 protein ; Breast cancer ; Breast Neoplasms - genetics ; Breast Neoplasms, Male - genetics ; Cancer ; Cancer research ; Chile ; Data processing ; Epidemiology ; Exons ; Family Health ; Female ; Female genital diseases ; Founder Effect ; Gel electrophoresis ; Gene mutations ; Gene Rearrangement ; Genes ; Genes, BRCA1 ; Genes, BRCA2 ; Genetic aspects ; genomics ; Gynecology. Andrology. Obstetrics ; Health aspects ; Humans ; Introns ; Male ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Mutation ; Oncology ; Ovarian cancer ; Ovarian Neoplasms - genetics ; Point Mutation ; Risk ; Risk factors ; Risk groups ; Tumors</subject><ispartof>Breast cancer research and treatment, 2011-04, Vol.126 (3), p.705-716</ispartof><rights>Springer Science+Business Media, LLC. 2010</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 Springer</rights><rights>Springer Science+Business Media, LLC. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c574t-c76eb9c2a2c2431537eea4300793376ee533f65acf0ec2a7f9bd3de763bd5cfe3</citedby><cites>FETCH-LOGICAL-c574t-c76eb9c2a2c2431537eea4300793376ee533f65acf0ec2a7f9bd3de763bd5cfe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-010-1170-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-010-1170-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23982093$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20859677$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gonzalez-Hormazabal, Patricio</creatorcontrib><creatorcontrib>Gutierrez-Enriquez, Sara</creatorcontrib><creatorcontrib>Gaete, Daniel</creatorcontrib><creatorcontrib>Reyes, Jose M.</creatorcontrib><creatorcontrib>Peralta, Octavio</creatorcontrib><creatorcontrib>Waugh, Enrique</creatorcontrib><creatorcontrib>Gomez, Fernando</creatorcontrib><creatorcontrib>Margarit, Sonia</creatorcontrib><creatorcontrib>Bravo, Teresa</creatorcontrib><creatorcontrib>Blanco, Rafael</creatorcontrib><creatorcontrib>Diez, Orland</creatorcontrib><creatorcontrib>Jara, Lilian</creatorcontrib><title>Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>The distribution of BRCA1/2 germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean population, there are only two reports of mutation analysis of BRCA1/2 , and these included a low number of BC and/or OC patients. Moreover, the prevalence of BRCA1/2 genomic rearrangements in Chilean and in other South American populations is unknown. In this article, we present the mutation-detection data corresponding to a set of 326 high-risk families analyzed by conformation-sensitive gel electrophoresis and heteroduplex analysis. To determine the contribution of BRCA1/2 LGRs in Chilean BC patients, we analyzed 56 high-risk subjects with no pathogenic BRCA1/2 point mutations. Germline BRCA1 / 2 point mutations were found in 23 (7.1%) of the 326 Chilean families. Families which had at least three BC and/or OC cases showed the highest frequency of mutations (15.9%). We identified 14 point pathogenic mutations. Three recurrent mutations in BRCA1 (c.187_188delAG, c.2605_2606delTT, and c.3450_3453delCAAG) and three in BRCA2 (c.4969_4970insTG, c.5374_5377delTATG, and c.6503_6504delTT) contributed to 63.6 and 66.7% of all the deleterious mutations of each gene, which may reflect the presence of region-specific founder effects. Taken together BRCA1/2 recurrent point mutations account for 65.2% (15/23) of the BRCA1/2 (+) families. No large deletions or duplications involving BRCA1 / 2 were identified in a subgroup of 56 index cases negative for BRCA1/2 point mutations. Our study, which is the largest conducted to date in a South American population, provides a comprehensive analysis on the type and distribution of BRCA1/2 mutations and allelic variants.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>BRCA1 protein</subject><subject>BRCA2 protein</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms, Male - genetics</subject><subject>Cancer</subject><subject>Cancer research</subject><subject>Chile</subject><subject>Data processing</subject><subject>Epidemiology</subject><subject>Exons</subject><subject>Family Health</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Founder Effect</subject><subject>Gel electrophoresis</subject><subject>Gene mutations</subject><subject>Gene Rearrangement</subject><subject>Genes</subject><subject>Genes, BRCA1</subject><subject>Genes, BRCA2</subject><subject>Genetic aspects</subject><subject>genomics</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Introns</subject><subject>Male</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Point Mutation</subject><subject>Risk</subject><subject>Risk factors</subject><subject>Risk groups</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9ktuO0zAQhiMEYruFB-AGWaAFbrL1IY7jy1JxklZC4nAduc649ZLYxU6Q-vZMaWFZBMgX1mi-mdE_8xfFI0YvGaVqkRmVlS4poyVjipb7O8WMSSVKxZm6W8woq1VZN7Q-K85zvqaUakX1_eKM00bqWqlZkT7uwI5pGkh05OWH1ZItONlFH0YyTKMZfQyZmNCRDYQ4eEsSmJRM2MAAYczEB7L1m22ZfP5C1pjM4yJ-M8mbQKwJFhJZbX0PGDoz-N5DflDcc6bP8PD0z4vPr199Wr0tr96_ebdaXpVWqmosraphrS033PJKMCkUgKkE6tZCYA6kEK6WxjoKSCmn153oQNVi3UnrQMyL58e-uxS_TpDHdvDZQt-bAHHKbYNjGt5ohuSL_5KMMqWbmlca0Sd_oNdxSgF1YL-mUkxSidDTI7QxPbQ-uDgmYw8926WQUgtd8UOry79Q-DrARccADvd2u-DZbwVbMP24zbGffhzpNsiOoE0x5wSu3SU_mLRHJe3BOe3ROS09xOicdo81j0_CpvUA3a-Kn1ZB4OIEmGxN79AE1ucbTuiGUzzNvOBHLmMKfZJuNvTv6d8BAkTZcQ</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>Gonzalez-Hormazabal, Patricio</creator><creator>Gutierrez-Enriquez, Sara</creator><creator>Gaete, Daniel</creator><creator>Reyes, Jose M.</creator><creator>Peralta, Octavio</creator><creator>Waugh, Enrique</creator><creator>Gomez, Fernando</creator><creator>Margarit, Sonia</creator><creator>Bravo, Teresa</creator><creator>Blanco, Rafael</creator><creator>Diez, Orland</creator><creator>Jara, Lilian</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20110401</creationdate><title>Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families</title><author>Gonzalez-Hormazabal, Patricio ; Gutierrez-Enriquez, Sara ; Gaete, Daniel ; Reyes, Jose M. ; Peralta, Octavio ; Waugh, Enrique ; Gomez, Fernando ; Margarit, Sonia ; Bravo, Teresa ; Blanco, Rafael ; Diez, Orland ; Jara, Lilian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c574t-c76eb9c2a2c2431537eea4300793376ee533f65acf0ec2a7f9bd3de763bd5cfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>BRCA1 protein</topic><topic>BRCA2 protein</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms, Male - genetics</topic><topic>Cancer</topic><topic>Cancer research</topic><topic>Chile</topic><topic>Data processing</topic><topic>Epidemiology</topic><topic>Exons</topic><topic>Family Health</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Founder Effect</topic><topic>Gel electrophoresis</topic><topic>Gene mutations</topic><topic>Gene Rearrangement</topic><topic>Genes</topic><topic>Genes, BRCA1</topic><topic>Genes, BRCA2</topic><topic>Genetic aspects</topic><topic>genomics</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Introns</topic><topic>Male</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Point Mutation</topic><topic>Risk</topic><topic>Risk factors</topic><topic>Risk groups</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonzalez-Hormazabal, Patricio</creatorcontrib><creatorcontrib>Gutierrez-Enriquez, Sara</creatorcontrib><creatorcontrib>Gaete, Daniel</creatorcontrib><creatorcontrib>Reyes, Jose M.</creatorcontrib><creatorcontrib>Peralta, Octavio</creatorcontrib><creatorcontrib>Waugh, Enrique</creatorcontrib><creatorcontrib>Gomez, Fernando</creatorcontrib><creatorcontrib>Margarit, Sonia</creatorcontrib><creatorcontrib>Bravo, Teresa</creatorcontrib><creatorcontrib>Blanco, Rafael</creatorcontrib><creatorcontrib>Diez, Orland</creatorcontrib><creatorcontrib>Jara, Lilian</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonzalez-Hormazabal, Patricio</au><au>Gutierrez-Enriquez, Sara</au><au>Gaete, Daniel</au><au>Reyes, Jose M.</au><au>Peralta, Octavio</au><au>Waugh, Enrique</au><au>Gomez, Fernando</au><au>Margarit, Sonia</au><au>Bravo, Teresa</au><au>Blanco, Rafael</au><au>Diez, Orland</au><au>Jara, Lilian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>126</volume><issue>3</issue><spage>705</spage><epage>716</epage><pages>705-716</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>The distribution of BRCA1/2 germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean population, there are only two reports of mutation analysis of BRCA1/2 , and these included a low number of BC and/or OC patients. Moreover, the prevalence of BRCA1/2 genomic rearrangements in Chilean and in other South American populations is unknown. In this article, we present the mutation-detection data corresponding to a set of 326 high-risk families analyzed by conformation-sensitive gel electrophoresis and heteroduplex analysis. To determine the contribution of BRCA1/2 LGRs in Chilean BC patients, we analyzed 56 high-risk subjects with no pathogenic BRCA1/2 point mutations. Germline BRCA1 / 2 point mutations were found in 23 (7.1%) of the 326 Chilean families. Families which had at least three BC and/or OC cases showed the highest frequency of mutations (15.9%). We identified 14 point pathogenic mutations. Three recurrent mutations in BRCA1 (c.187_188delAG, c.2605_2606delTT, and c.3450_3453delCAAG) and three in BRCA2 (c.4969_4970insTG, c.5374_5377delTATG, and c.6503_6504delTT) contributed to 63.6 and 66.7% of all the deleterious mutations of each gene, which may reflect the presence of region-specific founder effects. Taken together BRCA1/2 recurrent point mutations account for 65.2% (15/23) of the BRCA1/2 (+) families. No large deletions or duplications involving BRCA1 / 2 were identified in a subgroup of 56 index cases negative for BRCA1/2 point mutations. Our study, which is the largest conducted to date in a South American population, provides a comprehensive analysis on the type and distribution of BRCA1/2 mutations and allelic variants.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>20859677</pmid><doi>10.1007/s10549-010-1170-y</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0167-6806
ispartof Breast cancer research and treatment, 2011-04, Vol.126 (3), p.705-716
issn 0167-6806
1573-7217
language eng
recordid cdi_proquest_miscellaneous_857482891
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Adult
Biological and medical sciences
BRCA1 protein
BRCA2 protein
Breast cancer
Breast Neoplasms - genetics
Breast Neoplasms, Male - genetics
Cancer
Cancer research
Chile
Data processing
Epidemiology
Exons
Family Health
Female
Female genital diseases
Founder Effect
Gel electrophoresis
Gene mutations
Gene Rearrangement
Genes
Genes, BRCA1
Genes, BRCA2
Genetic aspects
genomics
Gynecology. Andrology. Obstetrics
Health aspects
Humans
Introns
Male
Mammary gland diseases
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Mutation
Oncology
Ovarian cancer
Ovarian Neoplasms - genetics
Point Mutation
Risk
Risk factors
Risk groups
Tumors
title Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A07%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Spectrum%20of%20BRCA1/2%20point%20mutations%20and%20genomic%20rearrangements%20in%20high-risk%20breast/ovarian%20cancer%20Chilean%20families&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Gonzalez-Hormazabal,%20Patricio&rft.date=2011-04-01&rft.volume=126&rft.issue=3&rft.spage=705&rft.epage=716&rft.pages=705-716&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-010-1170-y&rft_dat=%3Cgale_proqu%3EA355939429%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=858471505&rft_id=info:pmid/20859677&rft_galeid=A355939429&rfr_iscdi=true